Nine patients were studied retrospectively and 21 prospectively to ascertain the effectiveness and complications of three therapeutic regimens for life-threatening hypotensive reactions (systolic ...

Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) s ...